Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:OPTR
Raised
Post IPO Valuation
Acquired byCubist Pharmaceuticals
Price$535M
Date7/2013

General Information

Websiteoptimerpharma.com
CategoryBioTech
Phone858.909.0736
Employees

Offices

San Diego, USA
10110 Sorrento Valley Rd.
Suite C
San Diego, CA, 92121
USA

People

Chairman of the Boards of Directors
Chief Financial Officer & Senior Vice President, Finance
President & CEO
Board of Directors
Chief Scientific Officer & Senior Vice President, Research and Development

Tags

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer’s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Cubist Pharmaceuticals to buy Trius Therapeutics, Optimer Pharmaceuticals for up to $1.6 billion (firstwordpharma.com) [edit]
  2. Optimer lands $224M licensing pact for promising antibiotic (fiercebiotech.com) [edit]
Edit This Page
Last Edited 2/13/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy